The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Personalized medicine for DLBCL
Ulrich Jäger, MD, of Medical University of Vienna, Vienna, Austria, discusses applications of personalized therapy in diffuse large B-cell lymphoma (DLBCL) and highlights the importance of ongoing clinical trials investigating this approach. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
